Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - August 2016

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for August 2016 (PDF).

Following early termination of a clinical trial it is recommended that riociguat (Adempas®) should not be used to treat patients with pulmonary hypertension associated with idiopathic interstitial pneumonias. This medication should be under specialist supervision.

There is also a summary of letters sent to healthcare professionals in July including a letter advised that posaconazole (Noxafil®) tablets and suspension are not interchangeable and that inadvertent changes between the two formulations has led to under-dosing or over-dosing.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - August 2016' on Email Share 'Drug Safety Update - August 2016' on Delicious Share 'Drug Safety Update - August 2016' on Digg Share 'Drug Safety Update - August 2016' on Facebook Share 'Drug Safety Update - August 2016' on reddit Share 'Drug Safety Update - August 2016' on StumbleUpon Share 'Drug Safety Update - August 2016' on Twitter

atomic-wealth

One Comments to “Drug Safety Update - August 2016”

  1. […] This issue also contains additional information that posaconazole suspension and tablets are not dose equivalent as noted in the summary of letters to healthcare professionals in last month's update. […]

    Pingback by Drug Safety Update - September 2016 - Prescribing Advice For GPs — September 19, 2016 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer